Search
Plus Therapeutics Inc
PSTVAdd to Watchlist
4.160USD
-0.210-4.81%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
23.08MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Plus Therapeutics Inc is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 21.00 and a low of 2.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
36.000
Target Price
+723.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Plus Therapeutics Inc
PSTV
4
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Plus Therapeutics Inc's expected revenue for the next quarter?
Plus Therapeutics Inc's expected revenue is 1.36M.
What is Plus Therapeutics Inc's price target?
Analysts forecast that Plus Therapeutics Inc's price target is USD 4.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 2.00.
How have Plus Therapeutics IncPSTV's recent earnings per share performed?
The market expectation was USD -26.13, while Plus Therapeutics IncPSTV's earnings per share (EPS) for the previous quarter was USD -1.04. EPS for the next quarter is expected at USD -0.87.
What is the analyst rating for Plus Therapeutics Inc?
Based on the ratings of Plus Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.